Pharmaceutical companies have been reluctant to take part in cross-country health technology assessments (HTAs) offered by groups such as the recently revamped Joint Nordic HTA-Bodies (JNHB). Nevertheless, these initiatives are here to stay and companies should embrace the opportunities they offer, experts at the JNHB told the Pink Sheet in an interview.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?